Filing Flows › Entrada Therapeutics (TRDA) › Who owns the stock
Who owns Entrada Therapeutics (TRDA) stock
120 funds reported Entrada Therapeutics (TRDA) shares in their latest 13F filings, worth $248M in all. The largest holder is Baker Bros. Advisors LP ($37.3M). Last quarter 73 funds added to their stakes and 42 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 5,072,730 | $37.3M | unchanged | 2026-06-30 |
| 5AM Venture Management, LLC | 4,056,379 | $29.9M | unchanged | 2026-06-30 |
| MPM Asset Management LLC | 4,381,062 | $25.4M | unchanged | 2025-09-30 |
| BlackRock | 2,583,333 | $19.0M | increase | 2026-06-30 |
| Vanguard Group | 1,632,460 | $16.8M | increase | 2025-12-31 |
| Merck | 1,739,768 | $12.8M | new | 2026-06-30 |
| Vanguard Capital Management LLC | 1,269,634 | $9.3M | increase | 2026-06-30 |
| MPM BioImpact LLC | 1,253,053 | $9.2M | new | 2026-06-30 |
| TCG Crossover Management, LLC | 1,060,230 | $7.8M | decrease | 2026-06-30 |
| Wellington Management Group LLP | 954,419 | $7.0M | decrease | 2026-06-30 |
| Millennium Management LLC | 763,959 | $5.6M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 717,430 | $5.3M | increase | 2026-06-30 |
| AQR Capital Management LLC | 699,537 | $5.1M | increase | 2026-06-30 |
| Nantahala Capital Management, LLC | 601,150 | $4.4M | increase | 2026-06-30 |
| State Street | 596,677 | $4.4M | increase | 2026-06-30 |
Entrada Therapeutics' latest quarter
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most TRDA stock?
By the latest 13F filings: Baker Bros. Advisors LP ($37.3M); 5AM Venture Management, LLC ($29.9M); MPM Asset Management LLC ($25.4M); BlackRock ($19.0M); Vanguard Group ($16.8M).
What is the short interest in TRDA?
3,271,781 shares were sold short at the 2026-10-15 settlement, 9.44% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.